293 institutions hold shares in Amarin Corporation plc (AMRN), with 4.59M shares held by insiders accounting for 1.16% while institutional investors hold 39.53% of the company’s shares. The shares outstanding are 390.73M, and float is at 381.31M with Short Float at 5.77%. Institutions hold 39.07% of the Float.
The top institutional shareholder in the company is Baker Brothers Advisors, LLC with over 27.99 million shares valued at $136.88 million. The investor’s holdings represent 7.11% of the AMRN Shares outstanding. As of Dec 30, 2020, the second largest holder is Eversept Partners, LP with 15.94 million shares valued at $77.97 million to account for 4.05% of the shares outstanding. The other top investors are BVF Inc. which holds 10.76 million shares representing 2.74% and valued at over $52.62 million, while Boxer Capital, LLC holds 1.53% of the shares totaling 6.0 million with a market value of $29.34 million.
Amarin Corporation plc (NASDAQ: AMRN) is 32.52% higher on its value in year-to-date trading and has touched a low of $3.36 and a high of $9.25 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AMRN stock was last observed hovering at around $6.21 in the last trading session, with the day’s gains setting it 0.27% off its average median price target of $10.00 for the next 12 months. It is also 65.89% off the consensus price target high of $19.00 offered by 9 analysts, but current levels are -8.0% lower than the price target low of $6.00 for the same period.
Currently trading at $6.48, the stock is 4.42% and -6.61% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.62 million and changing 4.35% at the moment leaves the stock 10.03% off its SMA200. AMRN registered 30.12% gain for a year compared to 6-month gain of 53.92%. The firm has a 50-day simple moving average (SMA 50) of $6.51 and a 200-day simple moving average (SMA200) of $5.62.
The stock witnessed a 11.15% loss in the last 1 month and extending the period to 3 months gives it a 23.90%, and is 9.64% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.07% over the week and 6.43% over the month.
Amarin Corporation plc (AMRN) has around 1000 employees, a market worth around $2.44B and $614.10M in sales. Fwd P/E is 39.51. Profit margin for the company is -2.90%. Distance from 52-week low is 92.86% and -29.95% from its 52-week high. The company has generated returns on investments over the last 12 months (-3.30%).
Amarin Corporation plc (AMRN) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Amarin Corporation plc (AMRN) is a “Overweight”. 9 analysts offering their recommendations for the stock have an average rating of 2.40, where 4 rate it as a Hold and 0 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Amarin Corporation plc is expected to release its quarterly report on 08/04/2021 and quarterly earnings per share for the current quarter are estimated at -$0.03 with sales reaching $151.19M over the same period.The EPS is expected to grow by 28.70% this year, but quarterly earnings will post 7.20% year-over-year. Quarterly sales are estimated to grow 10.00% in year-over-year returns.
Amarin Corporation plc (AMRN) Insider Activity
A total of 5 insider transactions have happened at Amarin Corporation plc (AMRN) in the last six months, with sales accounting for 2 and purchases happening 3 times. The most recent transaction is an insider sale by Ketchum Steven B, the company’s Chief Scientific Officer. SEC filings show that Ketchum Steven B sold 217,728 shares of the company’s common stock on Feb 01 at a price of $8.06 per share for a total of $1.75 million. Following the sale, the insider now owns 0.38 million shares.
Amarin Corporation plc disclosed in a document filed with the SEC on Jan 27 that Ketchum Steven B (Chief Scientific Officer) sold a total of 421,629 shares of the company’s common stock. The trade occurred on Jan 27 and was made at $8.01 per share for $3.38 million. Following the transaction, the insider now directly holds 0.39 million shares of the AMRN stock.
Still, SEC filings show that on Nov 30, STACK DAVID M (Director) acquired 25,000 shares at an average price of $4.86 for $0.12 million. The insider now directly holds 25,000 shares of Amarin Corporation plc (AMRN).
Amarin Corporation plc (AMRN): Who are the competitors?
The company’s main competitors (and peers) include AstraZeneca PLC (AZN) that is trading 13.13% up over the past 12 months and Ionis Pharmaceuticals Inc. (IONS) that is -3.84% lower over the same period. AbbVie Inc. (ABBV) is 47.81% up on the 1-year trading charts. Short interest in the company’s stock has risen 8.37% from the last report on Feb 11, 2021 to stand at a total of 20.14 million short shares sold with a short interest ratio of 3.43.